Jotin Marango - 01 Feb 2024 Form 4 Insider Report for Ikena Oncology, Inc. (IKNA)

Reporting relationship: CFO & Head of Corp. Dev.
Issuer ticker: IKNA
Reported as of: 01 Feb 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 02 Feb 2024, 17:08:02 UTC
Prior SEC filing: 05 Jan 2023
Next SEC filing: 29 Jul 2025
Source filing: View source filing
Reporting owner signature: /s/ Mark Manfredi, as Attorney-in-Fact for Jotin Marango

Key filing fact

Jotin Marango filed Form 4 for Ikena Oncology, Inc. (IKNA) on 02 Feb 2024.

Key facts

This page summarizes Jotin Marango's Form 4 filing for Ikena Oncology, Inc. (IKNA).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 02 Feb 2024, 17:08.

Change

Previous filing in this sequence was filed on 05 Jan 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IKNA transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +181,000
Change %
Price: $0.000000
Shares after: 181,000
Date: 01 Feb 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 181,000
Exercise price: $1.36
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

25% of the shares subject to this option shall vest and become exercisable on January 1, 2025, with the remainder vesting in 36 substantially equal monthly installments thereafter.